Ocular Pain - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 70
Price : Single User: US $ 2000  US $ 1700 Corporate User: US $ 6000  US $ 4800
Inquire Before Buying
This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Ocular Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Ocular Pain - Pipeline Review, H2 2016', provides an overview of the Ocular Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Pain

- The report reviews pipeline therapeutics for Ocular Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ocular Pain therapeutics and enlists all their major and minor projects

- The report assesses Ocular Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ocular Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ocular Pain

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Ocular Pain - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ocular Pain Overview 7
Therapeutics Development 8
Pipeline Products for Ocular Pain - Overview 8
Ocular Pain - Therapeutics under Development by Companies 9
Ocular Pain - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Ocular Pain - Products under Development by Companies 13
Ocular Pain - Companies Involved in Therapeutics Development 14
D. Western Therapeutics Institute, Inc. 14
InSite Vision Incorporated 15
Kala Pharmaceuticals, Inc. 16
Ocular Therapeutix, Inc. 17
Reata Pharmaceuticals, Inc. 18
Sylentis S.A.U. 19
Valeant Pharmaceuticals International, Inc. 20
Ocular Pain - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
(bromfenac sodium + dexamethasone acetate) - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
bromfenac sodium - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dexamethasone acetate SR - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Drug for Ocular Pain - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ISV-705 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ketorolac tromethamine - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
loteprednol etabonate - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
loteprednol etabonate next generation - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
NT-71 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NT-72 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
omaveloxolone - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
RX-10045 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
SYL-1001 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Ocular Pain - Dormant Projects 59
Ocular Pain - Product Development Milestones 60
Featured News & Press Releases 60
Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite 60
Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome 60
Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit 61
Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite 61
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 62
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 62
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 63
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 63
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64
Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 64
Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 65
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 66
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 67
Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables
Number of Products under Development for Ocular Pain, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Ocular Pain - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 14
Ocular Pain - Pipeline by InSite Vision Incorporated, H2 2016 15
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 16
Ocular Pain - Pipeline by Ocular Therapeutix, Inc., H2 2016 17
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 18
Ocular Pain - Pipeline by Sylentis S.A.U., H2 2016 19
Ocular Pain - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Assessment by Combination Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Ocular Pain - Dormant Projects, H2 2016 59

List of Figures
Number of Products under Development for Ocular Pain, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Targets, H2 2016 23
Number of Products by Stage and Targets, H2 2016 23
Number of Products by Mechanism of Actions, H2 2016 25
Number of Products by Stage and Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29
  • United States Ophthalmic Drugs Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 101
    In this report, the United States Ophthalmic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of......
  • Global Eye Drops & Lubricants Market Professional Survey Report 2017
    Published: 15-Aug-2017        Price: US 3500 Onwards        Pages: 106
    This report studies Eye Drops & Lubricants in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Bausch + Lomb - Abbott - Clear Eyes - Sager Pharma - A......
  • Global Ophthalmic Drugs Sales Market Report 2017
    Published: 11-Aug-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global Ophthalmic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Ophthalmic Drugs for these regions, from 2012 to 2022 (forecast) , covering - United States - China - Europe - Japan......
  • Global Ophthalmic Drugs Market Research Report 2017
    Published: 07-Aug-2017        Price: US 2900 Onwards        Pages: 109
    In this report, the global Ophthalmic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ophthalmic Drugs in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - J......
  • Global Ophthalmology Amniotic Membrane Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 04-Aug-2017        Price: US 3480 Onwards        Pages: 116
    Amniotic membrane (AM) can function in the eye as a basement membrane substitute or as a temporary graft. It has anti-inflammatory and anti-scarring effects and contains growth factors that promote epithelial wound healing on the surface of the eye.Scope of the Report:This report focuses on the Ophthalmology Amniotic Membrane in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market bas......
  • China Eye Drops & Lubricants Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
    Published: 04-Aug-2017        Price: US 4480 Onwards        Pages: 121
    Eye drops are saline-containing drops used as an ocular route to administer. Depending on the condition being treated, they may contain steroids, antihistamines, sympathomimetics, beta receptor blockers, parasympathomimetics, parasympatholytics, prostaglandins, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, antifungal, or topical anesthetics. Eye drops sometimes do not have medications in them and are only lubricating and tear-replacing solutions.Scope of the Report:......
  • 2017 Top 5 Artificial Tears Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 03-Aug-2017        Price: US 4960 Onwards        Pages: 168
    "This report will be delivered in 2-3 business days after the order is placed." The Global Artificial Tears market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Artificial Tears in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Artificial Tears Players in each ......
  • 2017-2022 China Artificial Tears Market Report (Status and Outlook)
    Published: 03-Aug-2017        Price: US 3360 Onwards        Pages: 117
    "This report will be delivered in 2-3 business days after the order is placed." The Artificial Tears market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include Allergan Alcon (Novartis) Bausch & Lomb Abbott Santen Pharmaceutical......
  • 2017-2022 Global Top Countries Artificial Tears Market Report
    Published: 03-Aug-2017        Price: US 4960 Onwards        Pages: 168
    "This report will be delivered in 2-3 business days after the order is placed." The Global Artificial Tears market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Artificial Tears in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs